CCA
GILD icon

Carrera Capital Advisors’s Gilead Sciences GILD Stock Holding History

Carrera Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,505
Closed -$210K – 214
2026
Q1 		$210K Buy
+1,505
New +$211K 0.03% 176
2025
Q2 		– Sell
-34,696
Closed -$3.89M – 156
2025
Q1 		$3.89M Buy
34,696
+1,296
+4% +$134K 0.86% 19
2024
Q4 		$3.09M Buy
33,400
+7,854
+31% +$707K 0.72% 24
2024
Q3 		$2.14M Buy
25,546
+4,886
+24% +$373K 0.52% 40
2024
Q2 		$1.42M Buy
+20,660
New +$1.38M 0.46% 38

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Carrera Capital Advisors's GILD Position: Q2 2026 in Review

Carrera Capital Advisors sold out of Gilead Sciences (GILD) in Q2 2026, closing a stake of 1,505 shares — an estimated $210K sold.

Carrera Capital Advisors first reported a position in GILD in Q2 2024 and held it in 5 quarters. The position peaked at $3.89M in Q1 2025. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Carrera Capital Advisors reported no remaining Gilead Sciences position as of Q2 2026 after selling out during the quarter.
  • Carrera Capital Advisors sold 1,505 Gilead Sciences shares in Q2 2026, an estimated $210K.
  • Carrera Capital Advisors first reported a position in Gilead Sciences in Q2 2024 and held it in 5 quarters.
  • Carrera Capital Advisors's Gilead Sciences position peaked at $3.89M in Q1 2025.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Carrera Capital Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.